Nutrition, Overgrowth, and Vaccine Efficacy in Low-income Settings (NOVEL)

May 13, 2019 updated by: William Petri, MD, University of Virginia

A Longitudinal Study of Childhood Intestinal Bacterial Overgrowth, Vaccine Underperformance, and Malnutrition

The purpose of this study is to assess the impact of small intestine bacterial overgrowth (SIBO) on childhood nutritional status, growth, and oral vaccine efficacy.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

270

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Dhaka, Bangladesh
        • The International Centre for Diarrhoeal Disease Research, Bangladesh

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 1 week (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Bangladeshi infants from the low-income neighborhood of Mirpur, Dhaka

Description

Inclusion Criteria:

  • Child previously enrolled in the FIELD STUDIES protocol (enrollments in both studies may occur simultaneously)
  • Mother willing to sign informed consent form.
  • Healthy infant aged less than 7 days old

Exclusion Criteria:

  • Parents are not willing to have child's blood drawn, oral fluid collected, urine collected, or breath testing performed.
  • History of seizures, other apparent neurologic disorders, or other congenital abnormalities involving major organ systems.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glucose-Hydrogen Breath Test
Time Frame: Birth to 2 years
Test for Small Intestine Bacterial Overgrowth
Birth to 2 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Fecal Regenerating Islet-Derived 1 Beta (Reg 1B)
Time Frame: Birth to 2 years
Birth to 2 years
Fecal Myeloperoxidase
Time Frame: Birth to 2 years
Birth to 2 years
Serum 25-OH vitamin D
Time Frame: Birth to 2 years
Birth to 2 years
Serum Zinc
Time Frame: Birth to 2 years
Birth to 2 years
Serum Retinol Binding Protein
Time Frame: Birth to 2 years
Birth to 2 years
Serum Cobalamin
Time Frame: Birth to 2 years
Birth to 2 years
Serum Albumin
Time Frame: Birth to 2 years
Birth to 2 years
Lactulose mannitol ratio
Time Frame: 12 weeks of age
12 weeks of age
Serum Tetanus antibody titers
Time Frame: Birth to 2 years
Birth to 2 years
Serum Polio antibody titers to sabin strains
Time Frame: Birth to 2 years
Birth to 2 years
Oral fluid Tetanus antibody titers
Time Frame: Birth to 2 years
Birth to 2 years
Height
Time Frame: Birth to 2 years
Birth to 2 years
Weight
Time Frame: Birth to 2 years
Birth to 2 years
Head circumference
Time Frame: Birth to 2 years
Birth to 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: William A Petri, M.D., PhD, University of Virginia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2014

Primary Completion (Actual)

December 1, 2018

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

April 15, 2016

First Submitted That Met QC Criteria

April 19, 2016

First Posted (Estimate)

April 20, 2016

Study Record Updates

Last Update Posted (Actual)

May 15, 2019

Last Update Submitted That Met QC Criteria

May 13, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • PR14083

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Small Intestine Bacterial Overgrowth

3
Subscribe